The value of the managed entry of new drugs: A case study of donepezil

International Journal of Technology Assessment in Health Care

Volumn 19, Issue 1, 2003, Pages 114-128

  Payne, Katherine ^a   Davies, Linda M ^a   Noyce, Peter R ^a   Weiss, Marjorie C ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Alzheimer disease; Cholinesterase inhibitors; Cost effectiveness analysis; Economics; Pharmaceutical

Indexed keywords

COST EFFECTIVENESS; DATA PROCESSING; DECISION MAKING; DRUG THERAPY; MATHEMATICAL MODELS; STATISTICAL METHODS;

PROBABLISTIC SENSITIVITY ANALYSIS;

HEALTH CARE;

DONEPEZIL;

ANALYTIC METHOD; ARTICLE; COGNITION; CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; EVALUATION; HUMAN; PROBABILITY; STATISTICAL ANALYSIS;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG EVALUATION; DRUGS, INVESTIGATIONAL; GREAT BRITAIN; HEALTH CARE RATIONING; HUMANS; INDANS; ORGANIZATIONAL CASE STUDIES; PIPERIDINES; PRESCRIPTIONS, DRUG; PUBLIC HEALTH ADMINISTRATION; STATE MEDICINE;

EID: 0037412511     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462303000114     Document Type: Article

References (34)

1. Automobile Association. A to B. London: Automobile Association; April 1999.
2. Birks JS, Melzer D. Donepezil for mild to moderate Alzheimer's disease. The Cochrane Library. 1999;issue 1;1-14.
3. Briggs A, Sculpher M. Sensitivity analysis in economic evaluation: A review of published studies. Health Econ. 1995;4:355-371.
4. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Econ. 1994;3:95-104.
5. Buetow SA, Sibbald BS, Cantrill JA, Halliwell S. Prevalence of potentially inappropriate long term prescribing in general practice in the United Kingdom, 1980-95: Systematic literature review. BMJ. 1996;313:1371-1374.
6. Buetow SA, Sibbald B, Cantrill JA, Halliwell S. Appropriateness in health care: Application to prescribing. Soc Sci Med. 1997;45:261-271.
7. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: A practical approach. Med Decis Making. 1985;5:157-177.
8. Dyer O. Multiple sclerosis drug prompts rationing fears. BMJ. 1995;311:969.
9. Ely M, Melzer D, Brayne C, et al. The cognitively frail elderly: Estimating population characteristics and needs of people with cognitive disability, including dementia. Report to the NHS Executive Mental Health Research & Development Programme. 1995.
10. Fitzpatrick RW. Is there a place for Drug and Therapeutics Committees in the new NHS? Environ Health Perspect. 1997;3:143-147.
11. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
12. Guyatt GH, Cook DJ, Sackett DL, Eckman M, Pauker S. Grades of recommendation for antithrombotic agents. Chest. 1998;114(suppl):441s-444s.
13. Harvey RJ. A review and commentary on a sample of 15 UK guidelines for the drug treatment of Alzheimer's disease. International Journal of Geriatric Psychiatry. 1999;14(4):249-256.
14. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: A collaborative study of 1980-1990 findings. Int J Epidemiol. 1991;20:736-748.
15. International medical statistics. Pinner: International Medical Statistics; August 1998.
16. Kavanagh S, Knapp M. Cognitive disability and direct care costs for elderly people. Br J Psychiatry. 1999;174;539-546.
17. Kelly C, Harvey R, Cayton H. Drug treatments for Alzheimer's disease. BMJ. 1997;314:693-694.
18. Kurji KH, Haines AP. Detection and management of hypertension in general practices in North West London. BMJ. 1984;288:903-906.
19. Leach R, Leach S. Drug and therapeutics committees in the United Kingdom in 1992. Pharmaceutical Journal. 1994;253:61-63.
20. Melzer D, Hopkins S, Pencheon D, Brayne C, Willimas R. Dementia. In Stevens A, Raftery J, eds. Health care needs assessment. Vol 1. Oxford: Radcliffe Medical Press; 1994:chapter 16.
21. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 1999;52:1138-1145.
22. Neumann PJ, Sanberg EA, Araki SS, et al. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med Decis Making. 2000;20:413-422.
23. NHS Executive. Burdens of disease. Leeds: NHS E;1991.
24. NHS Executive. Purchasing and prescribing. Leeds: NHS E; 1994. EL(94)72.
25. NHS Executive North West. Travel expenses. Leeds: NHS E; 1998.
26. Novella JL, Jochum C, Jolly D, et al. Agreement between patients' and proxies' reports of quality of life in Alzheimer's disease. Qual Life Res. 2001;10:443-452.
27. Payne K. The economic impact of decision-making in relation to the introduction of drugs into practice. Manchester: University of Manchester; 2000.
28. Population estimates unit. London: Office of National Statistics;1998.
29. Rosen WG, Mohs RC, Davies KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
30. Rous E, Coppel A, Haworth J, Noyce S. A purchaser experience of managing New expensive drugs: Interferon beta. BMJ. 1996;313:1195-1196.
31. Stein K. Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type. Report to the Development and Evaluation Committee. 1997;69:1-35.
32. Stein K. Rivastigmine in the treatment of senile dementia of the Alzheimer type. Report to the Development and Evaluation Committee. 1998;89:1-37.
33. Stem D. Management of hypertension in twelve Oxfordshire general practices. J R Coll Gen Pract. 1986;36:549-551.
34. Wakeman A, Leach R. Joint prescribing committees: Characteristics, progress and effectiveness. Health Trends. 1997;29:52-54.